OSCIENT'S RAMOPLANIN STUDY RESULTS REPORTED

A A

Oscient Pharmaceuticals has presented new data on the in vitro activity of several products and product candidates against strains of Clostridium difficile (C. difficile), including recently described epidemic strains that have shown increased virulence. The data are among the first to report the in vitro activity of these agents against the strains of C. difficile suspected of causing recent cases of severe C. difficile-associated disease (CDAD).

The company's lead product candidate, Ramoplanin, a novel glycolipodepsipeptide antibiotic, was among the agents tested. Study results showed that Ramoplanin was highly active in vitro against all strains tested at concentrations below those clinically achievable in human trials and no resistance was observed.